Tue, Apr. 7, 12:45 PM
May 9, 2014, 12:57 PM
- Amyris (AMRS +12.6%) shoots higher despite missing Q1 earnings and revenue estimates, as CEO John Melo says the company is on track to become cash flow positive during H2 2014 and profitable in 2015.
- During this morning's earnings call, Melo said AMRS has resumed industrial production at the Brotas refinery in Brazil following planned maintenance and facility upgrades, and said the plant already achieved fermentation superior to last year's best fermentation runs.
- Melo also said AMRS now has more than 10 different partners and expects to add additional partners later this year.
- However, Cowen cuts its price target to $3 from $3.50, saying visibility remains low after Q1 results and 2014 outlook.
May 7, 2014, 11:36 AM
- Amyris (AMRS -7.1%) falls sharply for a second straight day after StreetSweeper writes that the maker of renewable fuel compounds faces rough times ahead, citing "onerous deals, SEC filings and extreme insider selling."
- The pessimistic view comes ahead of Thursday's earnings report after the company reported worse-than-expected earnings numbers over each of the past five quarters.
- Combined with disappointing Q1 earnings from Renewable Energy Group (REGI -5.3%), several biofuel names are trading lower: CDTI -8.5%, SZYM -7.3%, KIOR -6.4%, SYNM -4.3%, BIOF -2%, FF -1.5%.
Apr. 4, 2014, 9:10 AM
Apr. 3, 2014, 12:45 PM
Apr. 3, 2014, 9:09 AM
Feb. 26, 2014, 12:46 PM
Feb. 26, 2014, 11:20 AM
- Upgrading the stock to Market Perform from Underperform and boosting the price target to $3.50 from $3, Cowen analyst Robert Stone, notes reported revenue missed estimates by 17%, but two shipments totaling $4.5M were moved into 2014.
- "[Amyris] has achieved an 18% share in squalane, and inclusion in over 300 brands, some with multiple SKUs. The first F&F molecule (with Firmeniche) slipped from Q4 but has now shipped. A new collaboration with IFF anticipates a second molecule and brings in $20MM of funding. One to three additional F&F molecules could be in production in 2015. We believe five partners are currently working on as many as 22 F&F molecules."
- Stone cuts hus FY14 adjusted loss estimate to $0.75 per share from $0.80, and the FY15 loss to $0.35 from $0.45. Revenues are lifted to $180M from $95M in 2014, and $196M from $80M in 2015.
- AMRS +17.8%
Feb. 24, 2014, 12:39 PM
- Pulling out of a sizable slide this year, Amyris (AMRS +7%) today is up sharply on big volume ahead of Q4 results after the bell, but Cowen's Robert Stone continues with an Underperform and $3 price target.
- The company has about $76.3M in cash, but a burn rate, according to Stone, of $15M-$20M per quarter, meaning it could all be gone this year and a 40% dilution as early as the first conversion dates in 2015 Q1. If the stock remains above the $2.44 and $2.87 conversion prices, says Stone, paid-in-kind interest adds about 4% more shares annually.
Jan. 2, 2014, 12:45 PM
Dec. 27, 2013, 12:46 PM
Dec. 18, 2013, 8:24 AM
- Amyris (AMRS) +2.7% premarket after saying the number of city buses in Sao Paulo, Brazil, using the company's renewable diesel has increased to 400 from 300.
- Also, AMRS say it plans next year to begin production of its fragrance oil molecule from its own manufacturing facility in Brazil following the recent successful scale up of its fragrance oil at a specialty contract manufacturer.
Dec. 5, 2013, 10:28 AM
- Amyris (AMRS +3.9%) and Total (TOT -0.4%) form a 50-50 joint venture that holds exclusive rights and a license under AMRS' intellectual property to produce and market renewable diesel and jet fuel from AMRS' renewable farnesene.
- AMRS says the JV is a first step towards the commercialization of its renewable diesel and jet fuels.
- TOT is AMRS' largest shareholder with an ~18% stake.
May 16, 2013, 10:59 AMAmyris (AMRS -5.6%) takes a hit after the company is implicated in a class action lawsuit which claims it misled investors in 2011 and 2012 about its ability to produce Biofene in "commercially meaningful volumes." When the company changed its tone about production levels, the stock ultimately fell 48% from November 2011 to February 2012. (PR) | Comment!
Apr. 11, 2013, 9:10 AM
Apr. 11, 2013, 8:12 AMAmyris (AMRS) gets a lift before the bell as the company says its scientists used "simple baker's yeast strains to produce unprecedented concentrations of the precursor to the anti-malarial drug ingredient Artemisinin." Sanofi says it will use the semisynthetic artemisinin to produce between 80-150M ACT malaria treatments per year by 2014. AMRS shares +15.3% premarket. | Comment!
AMRS vs. ETF Alternatives
Amyris Inc is a renewable products company engaged in providing sustainable alternatives to petroleum-sourced products. It developed microbial engineering and screening technologies that modify the way microorganisms process sugars.
Other News & PR